Fenben is a widely used anthelmintic that was originally developed to deworm animals. However, animal research has shown that fenben also has potent antitumor properties against certain cancers. This article presents a case study of a woman with advanced non-small cell lung cancer who self-administered fenben for her own cancer treatment and experienced significant tumor shrinkage.
In vitro experiments showed that fenbendazole disrupts proteasomal function and microtubule dynamics of cancer cells, resulting in both cytostatic and cytotoxic effects. Similarly, in vivo studies demonstrated that when human lung adenocarcinoma (A549) cells were transplanted into athymic nu/nu mice, 1 mg/mouse fenbendazole was orally administered every 2 days for 12 days and resulted in a significant decrease of tumor size and weight.
Furthermore, a high-throughput assay showed that fenbendazole significantly inhibits the clonogenicity of EMT6 colon cancer cells in culture and reduces their numbers when administered in low concentrations over 24-h. This study also shows that fenbendazole has the ability to inhibit glucose uptake in cancer cells by blocking the GLUT4 protein’s linear movement across the microtubule, thereby starving cancer cells of insulin-fueled sugar.
Due to these positive animal and laboratory studies, many patients have decided to take fenben on their own and treat themselves with it. However, a large number of patients are experiencing adverse reactions to this drug and may need to alter their protocol or discontinue the medication entirely. This is largely due to the body’s detoxification reaction as it rids itself of the pathogens and toxins that are being targeted with fenben. This detox process can last a few weeks and is best done with the help of a trained oncologist. fenben for humans